Incidence of rotavirus gastroenteritis by age in African, Asian and European children: Relevance for timing of rotavirus vaccination

Figures & data

Table 1. Age of the children at the time of first vaccination in the European, African and Asian studies (total vaccinated cohort).

Study	Group	<1 month n (%)	1 month n (%)	2 months n (%)	3 months n (%)	4 months n (%)
European	HRV	–	230 (8.69)	1743 (65.87)	672 (25.40)	1 (0.04)
	Placebo	–	123 (9.12)	888 (65.88)	337 (25.00)	0 (0.00)
African	HRV-3 D	1 (0.06)	1549 (93.82)	101 (6.12)	–	–
	HRV-2 D	3 (0.18)	1565 (95.02)	79 (4.80)	–	–
	Placebo	2 (0.12)	1544 (94.09)	95 (5.79)	–	–
Asian	HRV	–	286 (5.34)	1912 (35.68)	3154 (58.85)	7 (0.13)
	Placebo	–	252 (4.71)	1943 (36.32)	3143 (58.76)	11 (0.21)

D = dose; HRV = human rotavirus vaccine.

n (%) = number (percentage) of children in the given category.

Figure 1 Incidence of any rotavirus gastroenteritis cases by age at onset in (A) Europe and (B) Africa Footnote: Data obtained from the total vaccinated cohort. D = dose; HRV = human rotavirus vaccine.

Figure 2 Incidence of severe rotavirus gastroenteritis cases by age at onset in (A) Europe (B) Africa and (C) Asia Footnote: Data obtained from the total vaccinated cohort. D = dose; HRV = human rotavirus vaccine.